Locating Sites For COVID-19 Antibody Treatments

Use these resources to identify sites of care administering COVID-19 antibody therapies.

**NICA COVID-19 Antibody Treatment Locator**

This is the most comprehensive database of sites administering COVID-19 antibody treatments currently available. NICA works closely with the distributor to add new treatment locations after each allocation period. NICA then processes this data to make it more consumer-friendly and help ensure our Locator listings reflect care settings rather than shipment receiving locations.

- Simply enter your city and state or your zip code and click “search”
- Click on a location to view site details including phone number, hours of operation, website, amenities, and more.
- If results do not populate for the area searched, try widening the search radius. If there are still no results to display, your state may not have opted into our locator program yet (see “Unlisted States” section below).

**HHS Protect Public Data Hub: Therapeutics Distribution Locations**

This national map is maintained by the Department of Health and Human Services and displays locations that have received shipments of COVID-19 antibody therapies.

- If results do not populate for the area searched, try widening the search radius. If there are still no results to display, your state may not have opted to have their locations displayed (see “Unlisted States” section below).
- It is important to note that locations are displayed based on the address where medication was shipped (e.g., centralized pharmacy, warehouse) and may not reflect the location/address where patient care is provided.

**Unlisted States**

If your state is not participating in either of the locator tools above, try one of the following:

- Contact your local/regional health authorities; or
- Call the Lilly COVID Hotline at 1-855-LillyC19 (1-855-545-5921) to inquire about sites that have received allocation of bamlanivimab in your area.
- Call Regeneron Medical Affairs at 1-844-734-6643 to inquire about sites that have received allocation of casirivimab/imdevimab in your area.